Ovid Therapeutics and Angelini Pharma entered into an exclusive license agreement to develop, manufacture and commercialize OV101 for the treatment of Angelman syndrome in Europe.

Kymera Therapeutics entered a strategic collaboration deal with Sanofi focused on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such as rheumatoid arthritis.

Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.

Molecular Partners aims to test a COVID-19 drug candidate on people during 2020, Chief Executive Patrick Amstutz said, as the Swiss company hopes that project will help it recover from the failure of the eye drug abicipar.

Sosei Group entered a discovery collaboration and licensing deal with AbbVie, initially focused on inflammatory and autoimmune diseases.

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).

AstraZeneca signed a tenth supply-and-manufacturing deal for the company’s experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.

Alpine Immune Sciences shares exploded 211 percent in premarket trading at news of a global option and license deal with AbbVie.

As AstraZeneca closes in on developing a vaccine against COVID-19, the U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020.

Emergent BioSolutions signed an $87 million deal to make AstraZeneca’s experimental COVID-19 vaccine in the United States.